Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: A systematic review and meta-analysis

E Schillebeeckx, JP van Meerbeeck… - European Respiratory …, 2021 - Eur Respiratory Soc
Malignant pleural mesothelioma (MPM) is characterised by late-stage diagnosis and poor
prognosis. Currently, no screening tool is advocated and diagnosis is based on invasive …

[PDF][PDF] The scent of COVID-19: viral (semi-) volatiles as fast diagnostic biomarkers?

K Lamote, E Janssens… - Journal of breath …, 2020 - repository.uantwerpen.be
Although reasonable endeavours have been taken to obtain all necessary permissions from
third parties to include their copyrighted content within this article, their full citation and …

Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: baseline results

K Zwijsen, E Schillebeeckx, E Janssens… - Journal of Breath …, 2023 - iopscience.iop.org
Pleural mesothelioma (PM) is an aggressive cancer of the serosal lining of the thoracic
cavity, predominantly caused by asbestos exposure. Due to nonspecific symptoms, PM is …

Exhaled breath analysis optimizes nodule management in a lung cancer screening program.

K Zwijsen, R Wener, E Janssens, E Schillebeeckx… - 2023 - Eur Respiratory Soc
Background: Lung cancer (LC) is the leading cause of cancer-related death worldwide,
accounting for almost a quarter of all cancer deaths. With the widespread use of (low-dose) …

[HTML][HTML] External validation of a breath-based prediction model for malignant pleural mesothelioma

E Janssens, E Schillebeeckx, K Zwijsen, J Raskin… - Cancers, 2022 - mdpi.com
Simple Summary Malignant pleural mesothelioma (MPM) is an incurable asbestos-related
thoracic cancer for which early-stage diagnosis remains a major challenge. Volatile organic …

Exhaled breath analysis predicts treatment response in malignant pleural mesothelioma patients.

E Heirwegh, E Schillebeeckx, E Janssens, V Surmont… - 2023 - Eur Respiratory Soc
Background: Malignant pleural mesothelioma (MPM) has a poor prognosis, and treatment
options have limited effects on survival. However, personalised treatment could benefit patient’…

Defining a new diagnostic biomarker panel for malignant pleural mesothelioma using a novel proteomic technique.

E Schillebeeckx, E Fernandez, A Staes… - 2023 - Eur Respiratory Soc
Introduction: Invasive diagnostic techniques contribute to a late diagnosis and hence poor
prognosis in patients with malignant pleural mesothelioma (MPM). Blood biomarkers, in …

Lung cancer screening by volume computed tomography: thriving to high performance

E Schillebeeckx, K Lamote - Breathe, 2021 - Eur Respiratory Soc
Low-dose volume CT screening for lung cancer leads to a significant decrease in lung-
cancer-related mortality. However, optimisation of the post-screening protocol will be crucial …

Breath analysis allows to predict treatment response in malignant pleural mesothelioma patients

E Schillebeeckx, E Janssens, V Surmont, K Nackaerts… - 2021 - Eur Respiratory Soc
Introduction: The current follow-up procedure for malignant pleural mesothelioma (MPM)
patients is suboptimal and predictive markers are lacking. Aims: Investigate whether valatile …

A novel proteomic technique to identify new diagnostic biomarkers for malignant pleural mesothelioma: a feasibility study

E Schillebeeckx, E Fernandez, J Van Meerbeeck… - 2021 - Eur Respiratory Soc
Introduction: Invasive diagnostic techniques contribute to a late diagnosis and hence poor
prognosis in patients with malignant pleural mesothelioma (MPM). Blood biomarkers, in …